Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 1452458-86-4 Chemical Structure| 1452458-86-4

Structure of Nacubactam
CAS No.: 1452458-86-4

Chemical Structure| 1452458-86-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Nacubactam, also known as RG-6080, FPI-1459, and OP-0595, is a beta-lactamase inhibitor used for treating bacterial infections.

Synonyms: OP0595 free acid

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Nacubactam

CAS No. :1452458-86-4
Formula : C9H16N4O7S
M.W : 324.31
SMILES Code : NCCONC(=O)[C@@H]1CC[C@@H]2C[N@]1C(=O)N2OS(O)(=O)=O
Synonyms :
OP0595 free acid
MDL No. :MFCD28986228
InChI Key :RSBPYSTVZQAADE-RQJHMYQMSA-N
Pubchem ID :73386748

Safety of Nacubactam

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H228-H315-H319
Precautionary Statements:P240-P210-P241-P264-P280-P302+P352-P370+P378-P337+P313-P305+P351+P338-P362+P364-P332+P313
Class:4.1
UN#:1325
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Enterobacter cloacae 1-256 μg/ml Evaluate the antibacterial activity of Nacubactam against Enterobacter cloacae Antimicrob Agents Chemother. 2018 Aug 27;62(9):e02596-17
Escherichia coli 1-256 μg/ml Evaluate the antibacterial activity of Nacubactam against Escherichia coli Antimicrob Agents Chemother. 2018 Aug 27;62(9):e02596-17
Klebsiella pneumoniae 1-256 μg/ml Evaluate the antibacterial activity of Nacubactam against Klebsiella pneumoniae Antimicrob Agents Chemother. 2018 Aug 27;62(9):e02596-17
Double-carbapenemase-producing Enterobacterales 4 mg/L To evaluate the antibacterial activity of Nacubactam in combination with aztreonam or cefepime against double-carbapenemase-producing Enterobacterales. Results showed that aztreonam/nacubactam was active against the whole collection (57/57; 100% susceptibility), with MIC50/MIC90 values of 1/2 mg/L. Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0092424
Escherichia coli 1:1 ratio to meropenem Test the susceptibility of Nacubactam in combination with meropenem against E. coli expressing KPC variants, showing all strains were susceptible to the combination Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00432-19
Klebsiella pneumoniae 1:1 ratio to meropenem Test the susceptibility of Nacubactam in combination with meropenem against KPC-producing K. pneumoniae, showing all strains were susceptible to the combination Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00432-19
28 MABC clinical isolates 8 μg/ml 3 days To evaluate the in vitro activity of Nacubactam in combination with β-lactam antibiotics against 28 MABC clinical isolates. Results showed that Nacubactam significantly reduced the meropenem MIC50 from 32 μg/ml to 4 μg/ml, changing the interpretation from resistant to susceptible or intermediate for all isolates. Antimicrob Agents Chemother. 2019 Aug 23;63(9):e00733-19
Mycobacterium abscessus ATCC 19977T 4 or 8 μg/ml 3 days To evaluate the in vitro activity of Nacubactam in combination with β-lactam antibiotics against M. abscessus ATCC 19977T. Results showed that Nacubactam significantly lowered the MICs of its partner β-lactams, such as meropenem, by up to 8-fold. Antimicrob Agents Chemother. 2019 Aug 23;63(9):e00733-19
Enterobacter cloacae 2 to 256 μg/ml Evaluate the inhibitory effect of Nacubactam on KPC or IMI-type β-lactamase-producing strains Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02382-18
Escherichia coli 2 to 256 μg/ml Evaluate the inhibitory effect of Nacubactam on KPC or IMI-type β-lactamase-producing strains Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02382-18
Klebsiella pneumoniae 2 to 256 μg/ml Evaluate the inhibitory effect of Nacubactam on KPC or IMI-type β-lactamase-producing strains Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02382-18
E. coli TOP10 recombinant strains 4 µg/mL Evaluate the inhibitory activity of Nacubactam against AmpC β-lactamases. Results showed significant inhibition against most AmpC enzymes but poor inhibition against ADC-50 and PDC-382. Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0077524
P. aeruginosa PAO1 4 mg/mL Evaluate the antibacterial activity of Nacubactam against P. aeruginosa PAO1, results showed that Nacubactam alone had an MIC >32 mg/mL, and when combined with meropenem, it was effective against most recombinant strains but not against class B β-lactamase producers Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0033923
E. coli TOP10 4 mg/mL Evaluate the antibacterial activity of Nacubactam against E. coli TOP10, results showed that Nacubactam alone had an MIC of 8 mg/mL, and when combined with meropenem, it significantly reduced the MIC values Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0033923

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
ICR mice Neutropenic murine pneumonia model Subcutaneous injection 320, 160, and 80 mg/kg q8h Every 8 hours for 24 hours Evaluate the in vivo antimicrobial activity of Nacubactam alone or combined with β-lactams against pneumonia caused by CRE and CPE Antibiotics (Basel). 2021 Sep 28;10(10):1179
BALB/c mice Pneumonia model Intraperitoneal injection 20 mg/kg OP0595 and 100 mg/kg FEP Twice a day until 108 hours postinoculation To evaluate the efficacy of the combination therapy of OP0595 and FEP in a mouse model of pneumonia caused by ESBL-producing K. pneumoniae. Results showed that the combination significantly improved survival rates and reduced bacterial counts in lungs and blood. Antimicrob Agents Chemother. 2017 Jun 27;61(7):e00828-17
Mice Neutropenic murine complicated UTI (cUTI) model Subcutaneous injection 80 mg/kg, 20 mg/kg, 10 mg/kg Every 8 hours for 48 hours Evaluate the efficacy of Nacubactam alone or in combination with meropenem against complicated urinary tract infections Antimicrob Agents Chemother. 2018 Aug 27;62(9):e02596-17

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.08mL

0.62mL

0.31mL

15.42mL

3.08mL

1.54mL

30.83mL

6.17mL

3.08mL

 

Historical Records

Categories